EUVIMEDEUVIMED entdecken
Crossref

Long-term outcomes of thoracic endovascular aortic repair for descending thoracic aortic aneurysms based on pooled results from FDA clinical trials

Lauren A Gillinov, Grace J Wang, Nicholas J Goel, Michael A Catalano, Wilson Y Szeto, Venkat R Kalapatapu, Nimesh D Desai

Journal of Vascular Surgery · 2025

DOI: 10.1016/j.jvs.2025.05.038 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Vascular Surgery, 2025. Verfasst von Lauren A Gillinov und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA. Electronic address: lauren.gillinov@pennmedi…. Hauptthemen laut MEDLINE: Endovascular Procedures, Aortic Aneurysm, Thoracic, Blood Vessel Prosthesis Implantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Thoracic endovascular aortic repair (TEVAR) is the preferred treatment for descending thoracic aortic aneurysms, but long-term data are limited. This study assessed long-term results of TEVAR in early recipients of TEVAR devices who were enrolled in US Food and Drug Administration investigational device exemption clinical trials for aneurysm. METHODS: This was a single-center retrospective study including 179 patients enrolled in 14 clinical trials for TEVAR for descending thoracic aortic aneurysm between 2000 and 2019. The primary outcome was 10-year mortality. Secondary outcomes included a 30-day composite of death or a neurologic event, endoleak, reintervention, and aortic diameter on follow-up imaging. Descriptive statistics, Kaplan-Meier survival analysis, Cox proportional hazards models, and cumulative incidence functions with competing risk were used for analysis. RESULTS: The median patient age was 74 years and median follow-up was 5.5 years. Aneurysm morphology was fusiform (n = 100 [55.9%]) or saccular (n = 70 [39.1%]), with median preoperative diameter of 60.0 mm. Survival at 1, 5, and 10 years was 91.1%, 62.8%, and 31.4%. Endoleak was observed in 58 patients (32.4%), and reintervention in 44 patients (24.6%). Neither endoleak nor reintervention was associated with all-cause mortality at 10 years. Increasing age and preoperative aneurysm diameter were independent predictors of mortality. A majority of patients (73.8%) had stable aneurysm sac at 5 years. CONCLUSIONS: Although overall survival at 10 years was limited, early outcomes were favorable and most patients had stable aneurysm sac at 5 years. Endoleak and reintervention were not linked to long-term mortality, whereas age and preoperative aortic diameter predicted worse survival. In this older patient cohort, the durability of TEVAR remains a concern.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endovascular ProceduresAortic Aneurysm, ThoracicBlood Vessel Prosthesis ImplantationHumansMaleAgedFemaleRetrospective StudiesTreatment OutcomeTime FactorsUnited StatesRisk FactorsAged, 80 and overRisk AssessmentMiddle AgedClinical Trials as TopicUnited States Food and Drug AdministrationPostoperative ComplicationsBlood Vessel ProsthesisEndoleakEndovascular Aneurysm Repair

Stichwörter der Autor:innen

AneurysmDescending thoracic aortic aneurysmEndoleakTEVARThoracic endovascular aortic repair

Autor:innen und Institutionen

  • Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA. Electronic address: lauren.gillinov@pennmedicine.upenn.edu.
  • Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, University of Pennsylvania, Philadelphia, PA.
  • Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA.

Zitieren

APA

Gillinov, L. A., Wang, G. J., Goel, N. J., Catalano, M. A., Szeto, W. Y., Kalapatapu, V. R., & Desai, N. D. (2025). Long-term outcomes of thoracic endovascular aortic repair for descending thoracic aortic aneurysms based on pooled results from FDA clinical trials. Journal of Vascular Surgery. https://doi.org/10.1016/j.jvs.2025.05.038

Vancouver

Gillinov LA, Wang GJ, Goel NJ, Catalano MA, Szeto WY, Kalapatapu VR, et al. Long-term outcomes of thoracic endovascular aortic repair for descending thoracic aortic aneurysms based on pooled results from FDA clinical trials. Journal of Vascular Surgery. 2025. doi:10.1016/j.jvs.2025.05.038

BibTeX
@article{Gillinov2025,
  author = {Gillinov, Lauren A and Wang, Grace J and Goel, Nicholas J and Catalano, Michael A and Szeto, Wilson Y and Kalapatapu, Venkat R and Desai, Nimesh D},
  title = {Long-term outcomes of thoracic endovascular aortic repair for descending thoracic aortic aneurysms based on pooled results from FDA clinical trials},
  journal = {Journal of Vascular Surgery},
  year = {2025},
  doi = {10.1016/j.jvs.2025.05.038}
}
Kostenlos starten →